Employees Provident Fund Board Invests $25.69 Million in Amgen Inc. $AMGN

Employees Provident Fund Board bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 78,500 shares of the medical research company’s stock, valued at approximately $25,694,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of AMGN. Anfield Capital Management LLC raised its position in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC increased its position in Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen in the 4th quarter worth approximately $26,000. Manning & Napier Advisors LLC raised its position in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new position in Amgen in the 4th quarter worth $33,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on AMGN. Cantor Fitzgerald reissued a “neutral” rating and set a $350.00 price target on shares of Amgen in a report on Wednesday, April 8th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, June 14th. Morgan Stanley lifted their price target on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 9th. UBS Group upped their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Barclays assumed coverage on Amgen in a report on Friday, February 20th. They set an “equal weight” rating and a $350.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average target price of $354.42.

Amgen Price Performance

Amgen stock opened at $337.60 on Friday. The company has a market cap of $182.21 billion, a PE ratio of 23.49, a PEG ratio of 3.39 and a beta of 0.42. Amgen Inc. has a fifty-two week low of $267.83 and a fifty-two week high of $391.29. The business’s 50-day simple moving average is $340.71 and its two-hundred day simple moving average is $345.76. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts anticipate that Amgen Inc. will post 22.38 EPS for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.